AstraZeneca reported an 18% year-on-year increase in core earnings per share for Q2 2026, with revenue growth meeting full-year expectations. However, the company faces challenges as its top drug, Farxiga, approaches patent expiry in the U.S. and faces pressure from China's procurement program. Positive developments include promising results from its weight loss drug candidate, elecoglipron, and improved stock market valuations. Despite these positives, concerns over Farxiga's future impact on revenue growth remain central.
AstraZeneca reported a 21% increase in core earnings per share to $2.63 for Q2 2026, surpassing analyst expectations of $2.50. Total revenue rose 6% to $15.38 billion, driven by strong sales in oncology and rare disease drugs, offsetting pressure fro...
The FTSE 100 index gained 40 points to 10,777, supported by a drop in oil prices following a pause in US-Iran strikes and easing retail sector downturn. Retail sales improved in July, though online sales fell sharply, and wholesale volumes stabilized...
AstraZeneca reported second-quarter earnings that surpassed analyst expectations, with core earnings per share rising 21% to $2.63, though revenue slightly missed forecasts at $15.4 billion. Growth in oncology and rare diseases offset weaker sales fr...
